Sylentis | GenomeWeb


Gradalis has promoted Phillip Maples as executive vice president and chief technical officer.

This article has been updated to correct details regarding SYL1001's development timeline.

Title: Inducible Small RNA Expression Constructs for Targeted Gene Silencing
Patent Number: 8,198,077
Filed: Jan. 15, 2004
Lead Inventor: Thomas Tuschl, Max Plank Institute

Alnylam Pharmaceuticals said this week that it has granted Sylentis, a Spanish developer of RNAi drugs, a non-exclusive option to license certain of its RNAi-related intellectual property.

The company said the Spanish Agency for Medicines and Healthcare Products has cleared its lab to make pharmaceutical compounds for research.

Earlier this summer, the company completed a phase Ia trial, finding the agent to be safe and well-tolerated in healthy volunteers.

The drug targets adrenergic receptor beta-2 and is delivered topically to the eye.

An update on the RNAi drug pipelines for Alnylam, Calando, Pfizer, Quark, Silence Therapeutics, Sylentis, Tekmira, TransDerm, and Zabecor.

The first portion of the study was completed a few weeks ago, according to a company official, and the drug has been shown to be safe and well tolerated.

Overview of key RNAi-based therapeutics currently in human trials


In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.